Biotechnology Company Vivus Inc. announced that a Food and Drug Administration advisory committee will tentatively review recommendation or not for diet pill Qnexa (Phentamine + Topiramate) as soon as July 15th.

Last March 1st., the FDA scheduled a final review for the experimental drug for patients with weight loss, Diabetes Type II and hypertension problems.

Qnexa combines appetite suppressant Phentermine, a drug that was the key ingredient on former Wyeth drug “Fen-Phen”, in combination with anticonvulsant Topiramate, a generic J&J drug Topamax.

In view of the results, many private investment banks, such as JMP securities, forecast Qnexa approval and could reach sales of 2015 of 1.500 million dollars.